A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Durvalumab
DRUG: Paclitaxel
DRUG: Pertuzumab
DRUG: Tucatinib

Sponsor

AstraZeneca

Collaborators

[object Object]